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Abstract 
The discovery of drugs for Alzheimer’s disease (AD) therapy that can also permeate the blood brain barrier (BBB) is 
very difficult owing to its specificity and restrictive nature. The BBB disruption or the administration of the drug directly 
into the brain is not an option due to toxic effects and low diffusion of the therapeutic molecule in the brain parenchyma. 
A promising approach for drug systemic delivery to the central nervous system is the use of nanosized carriers. The 
therapeutic potential of certain nanopharmaceuticals for AD has already been demonstrated in vivo after systemic 
delivery. They are based on conjugates of drug and monoclonal antibodies against BBB endogenous receptors; 
cationized or end terminal protected proteins/peptides; liposomes and polymeric nanoparticles coated with polysorbate 
80, cationic macromolecules or antibodies against BBB receptors/amyloid beta-peptides. Optimization and further 
validation of these systems are needed. 
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INTRODUCTION 
Alzheimer’s disease (AD) is a neurodegenerative disorder of the human brain causing dementia. The majority of the 35 
million people who have dementia worldwide are thought to have AD (World Alzheimer's Report from Alzheimer's 
Disease International). The initial clinical symptoms of the disease are almost imperceptible and typically involve lapses 
of memory for recent facts and poor judgment [1]. The performance of complex work tasks and ability to acquire new 
information may be reduced. After a couple of years cognitive functions are affected and patients show spatial 
disorientation, apathy, general disinterest and difficulty in performing simple tasks such as preparing meals or managing 
bank accounts. Patients frequently lose emotional control, which may be accompanied by physical or verbal aggression. 
Symptoms of depression may prevail in the early stage of illness. With progression of the disease, patients develop 
motor problems showing difficulty for walking and manual activities like writing. Recent memory is severely affected. 
Over several years, the disease leads to a gradual deterioration of the life of the patients, who manifest a marked 
dementia with profound memory and cognition losses. Many patients become immobile and succumb to respiratory 
difficulties. 
AD is neuropathologically characterized by neuritic plaques and neurofibrillary tangles in regions of the brain 
particularly related to memory and cognition [2]. The neuritic plaques are spherical extracellular lesions that contain 
amyloid β-peptide fibrils surrounded by dystrophic axons and dendrites, activated microglia and reactive astrocytes. The 
amyloid β-peptide (Aβ) has 40 or 42 amino acids and is a normal metabolic product of enzymatic processing of a 
transmembranar protein, the amyloid precursor protein. The sequence of 40 residues is normally the more abundantly 
produced by cells. Amyloid plaques deposit in the brain parenchyma and around cerebral vessel walls. Diffuse plaques 
are also observed in the same brain regions in much larger number. They consist of amorphous extracellular deposits of 
Aβ (material that lack of fibrils). Diffuse plaques appear to represent an earlier stage of neuritic plaques. Neurofibrillary 
tangles are helical paired filaments composed largely of abnormal microtubular tau protein. These fibers are found in the 
cytoplasm of neurons. There are no peripheral biochemical markers for AD and confirmation still requires post-mortem 
observation of the classical lesions. 
The existing therapies for AD are based on the alleviation of its symptoms. Four of the five drugs approved for clinical 
use as treatment of cognitive symptoms, donepezil (Aricept®), rivastigmine (Exelon®), galantamine (Razadyne®) and 
tacrine (Cognex®), are inhibitors of the acetylcholinesterase (AChE), raising the levels of acetylcholine, a 
neurotransmitter that is deficient in the brains of patients with AD. Tacrine has limited use due its severe side effects. 
The other drug, memantine (Namenda®) is an uncompetitive antagonist of the N-methyl-D-aspartate receptor, regulating 
the activity of glutamate, which is released by cells damaged by the disease. Drug development in AD includes several 
strategies such as immunotherapy and inhibitors of Aβ aggregation, which result from the growing knowledge of Aβ 
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generation and the effects of Aβ oligomers (soluble aggregates) on the synaptic function [3, 4]. The development of AD 
drugs is a very active research area and many promising molecules reach the clinical trials but they end up failing [5]. 
One of the main reasons for that disappointing outcome is the poor blood brain barrier (BBB) permeation of the drugs. 
The BBB is anatomically defined as the cerebral microvascular endothelium, which is different from all other vascular 
beds as it has tight cell-cell junctions and few alternate transport pathways (e.g. decreased pinocytotic activity and 
significantly decreased number of intracellular fenestrae). The brain endothelial cells have extra degrading enzymes and 
additionally express high levels of active influx/efflux membrane transport proteins (e.g. P-glycoprotein, Multidrug 
Resistance Protein-1, Breast Cancer Resistance Protein) that limit the permeability of molecules. The BBB has other 
cells anatomically associated to the endothelium in particular pericytes and perivascular astrocytes that contribute to the 
regulation and maintenance of the BBB function and characteristics [6, 7]. Physiological and biochemical features will 
also affect the transport of molecules to the brain [8, 9]. Thus in brain drug delivery, factors such as the binding of the 
drug to albumin in the peripheral blood and the complex barrier layers of the central nervous system (the brain 
endothelium, the arachnoid epithelium and the choroid plexus epithelium) have to be considered. Another relevant 
question of molecule transport in AD is the BBB dysfunction [9], although it is now generally accepted that the barrier 
remains intact in early AD.  
Several strategies are being exploited for the delivery of AD drugs through the BBB [9-12]. In this review, the BBB 
drug-targeting strategies for AD that have been shown to have a therapeutic effect in AD transgenic rodent models 
and/or to increase the concentration of the drug in the brain of animal models after parenteral administration are 
discussed. These approaches include reengineering the drug molecule by coupling monoclonal antibodies (mAb) against 
BBB receptors, peptide cationization and/or other chemical modifications, and the use of liposomes and polymer-based 
nanoparticles coated with mAb, polysorbate 80 or trimethylated chitosan.  
 
TRANSPORT OF DRUGS THROUGH THE BBB  
Due to the tight junction between adjacent endothelial cells, most molecules are forced to cross the BBB via the 
transcellular route (Figure 1) [7, 13, 14]. Some small lipophilic molecules (molecular weight < 500 daltons) such as 
barbiturates and ethanol diffuse freely from the blood to the central nervous system. Other small molecules and 
macromolecules such as peptides and proteins are generally excluded unless they are essential molecules, which are 
transported through interaction with specific transporters and/or receptors expressed at the luminal (blood) side of the 
endothelial cells. The transcellular traffic of small hydrophilic essential molecules such as glucose, amino acids or 
nucleosides is regulated by specific transport proteins expressed at the luminal and abluminal membranes (carrier-
mediated transport and active efflux transport). Large hydrophilic essential molecules such as peptides and proteins are 
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transferred by endocytosis in vesicles, which can be either specific (receptor-mediated transcytosis) or less specific 
(adsorptive-mediated transcytosis) [7, 13, 14]. Certain endogenous large-molecules such as hormones, insulin, 
transferrin for iron, lipoproteins are transported to the brain across the BBB via receptor-mediated transcytosis (RMT), 
which is the transport through specialized ligand-specific receptor systems expressed at the luminal and basolateral side 
of the brain endothelial cells. Polycationic proteins such as protamine and cationized proteins (proteins with a basic 
isoelectric point) can bind to luminal plasma membrane of the brain endothelial cell and be transported through the BBB 
by adsorptive-mediated transcytosis (AMT), also known as the pinocytosis route [15-17]. The transport is triggered by 
the electrostatic interactions between the positively charged proteins and negatively charged regions of the membrane 
surface of brain endothelial cells.  
 
Figure 1. Schematic representation of the transport of molecules across the blood-brain barrier. Modified from Abbott, N. J. and 
Romero, I. A. Transporting therapeutics across the blood–brain barrier. Mol. Med. Today 2, 106–113 (1996). Copyright (1996), with 
permission from Elsevier. 
 
BBB drug-targeting approaches include invasive procedures (osmotic opening of the BBB, shunts and biodegradable 
implants), pharmacological approaches (modifying, through medicinal chemistry, a molecule) and physiological 
strategies that take advantage of the RMT and AMT pathways [14, 17]. Invasive procedures can be highly traumatic and 
often have low therapeutic efficiency with substantial side effects. Pharmacological approaches often result in loss of the 
central nervous system activity. RMT is the most accepted process in physiological strategy because of its specificity 
and the approaches comprise the association/conjugation of drugs to specific ligands that are recognized by the BBB 
endogenous receptors (Table 1). AMT-based strategies involve cationic liposomes/ nanoparticles, cell-penetrating 
peptides and cationization of proteins with diamine/polyamine (Table 1). The principal constraint of AMT is its lack of 
selectivity, which potentially can cause side effects of drugs in non-targeted organs. 
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Table 1. Specific ligands and other molecules used in 
physiological approaches to target drugs/ nanoparticles to the 
brain parenchyma through the BBB. 
 
Process Molecules 
Receptor 
mediated 
transport 
 
Transferrin 
 
Monoclonal antibodies against transferrin 
receptor and insulin receptor 
 
CRM197, a non toxic mutant of diphtheria toxin 
 
Low-density lipoprotein receptor (LRP) related 
proteins:  
Melanotransferrin  
Receptor associated protein  
LRP binding domain of the apolipoprotein B 
LRP binding Angiopep (19 amino acids peptide)  
Adsorptive 
mediated 
transport 
 
Diamine and polyamines:  
hexamethylenediamine (synthetic) 
putrescine, spermidine and spermine (naturally 
occurring) 
 
Cell penetrating peptides: 
Penetratin (derived from Antennapedia protein) 
TAT protein (HIV-1 trans-activating transcriptor) 
FBP (fusion sequence-based peptide)   
Syn-B (derived from a natural mammalian 
antimicrobial peptide) 
Poly-arginine peptides 
 
 
RE-ENGINEERING Aβ PEPTIDE AND AMYLOID ANTIBODIES  
The idea that amyloid plaques could be imaging in vivo by using labeled Aβ peptide came from the observation that 
radioiodinated Aβ40 binds specifically and reversibly to neuritic and diffuse plaques as well as cerebrovascular amyloid 
in brain tissues obtained from AD patients [18]. Studies using rats as animal models showed that the radiolabeled 
peptide was not able to cross the brain capillary endothelial wall [19]. Although Aβ40 was found to cross the BBB in 
other studies, the systemic factors proteolytic degradation and systemic clearance seem to be determinant in controlling 
the level of plasma Aβ [20-23]. Aβ peptides that circulate in the blood are assumed to adsorb to the brain 
microvasculature, nonspecifically, and to be rapidly metabolized without significant transport into the brain [5, 19]. The 
efflux of Aβ from the brain depends by its turn on the aggregation state of the peptide. Soluble Aβ monomers, but not 
dimers, are eliminated from the brain [24]. The strategies to delivering Aβ as an imaging agent to the brain include its 
conjugation to mAb or fusion antibodies against BBB receptors and polyamine modification (Figure 2).  Radioiodinated 
Aβ was conjugated to mAb against receptors of the BBB to enhance its transport through the BBB [19, 25-29]. The 
conjugation of 125I-labeled Aβ40 (125I-Aβ40) to a murine mAb to the rat transferrin receptor (OX26) was achieved by the 
streptavidin-biotin technology [19]. A spacer-biotin linker was used for 125I-Aβ40 monobiotinylation followed by binding 
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to streptavidin-OX26 mAb. The OX26 was conjugated to streptavidin by a thioether linkage. The spacer linker 
contributed to minimize the steric hindrance that could prevent the binding of 125I-Aβ40 to amyloid plaques. Combining 
monobiotinylated 125I-Aβ40 and streptavidin-OX26 mAb increased the delivery of the peptide to the brain and decreased 
the Aβ peripheral metabolism in anesthetized rats after intravenous (IV) injection [19]. The antibodies did not 
compromise the binding affinity of 125I-Aβ40 to amyloid plaques in frozen sections of AD brain. The OX-26 is specific 
for rats and aged rats do not show accumulation of amyloid plaques in the brain, hence the conjugation technology was 
extended to other mAb to validate the system in other animal models. Monobiotinylated radiolabeled Aβ40 was 
conjugated to 83-14 mAb to the human insulin receptor (animal model rhesus monkey) [25] and to RI7-217 or 8D3 rat 
mAb to the mouse transferrin receptor (animal model mice) [26, 27]. The work with primates has demonstrated that the 
complex 125I-Aβ40 /83-14 mAb also effluxes from the brain to the blood with a half-time of 16 h [25]. More recently, a 
fusion protein composed of a chimeric mAb against the mouse transferrin receptor (cTfRmAb) and avidin (AV) was 
tested as a carrier of the radiolabeled Aβ in rodent models [28]. The brain uptake of the complex monobiotinylated 125I-
Aβ40/cTfRmAb-AV is on the order of 2% injected dose (ID)/gram brain at 60 min after IV injection and is close to the 
brain uptake of small molecules proposed as amyloid imaging agents based on 8F-labeled benzofuran derivatives (3% 
ID/gram at 60 min after IV injection) [28, 30]. A similar system was prepared using the fusion protein of chimeric mAb 
to the human insulin receptor (HIRmAb) and avidin (AV) as a neuro-imaging agent for humans [29]. These fusion 
proteins are prepared by genetic engineering a gene, which encodes a fusion protein formed by the amino terminus of 
avidin linked to the carboxyl terminus of the heavy chain of the mAb [31].  
The polyamine modification of radioiodinated Aβ40 was achieved by amidation of the peptide carboxylic groups using a 
natural diamine (putrescine) and a water-soluble carbodiimide crosslinker that activates carboxyl groups [32, 33]. This 
modification increased the Aβ40 BBB permeability in a transgenic mouse model of AD after IV injection by at least 
twofold comparing to the labeled peptide and enhanced its binding to amyloid plaques in AD brain sections [32]. 
Gadolinium labeling was combined to the diamine modification to prepare an Aβ40 probe able to be detected by 
magnetic resonance imaging (MRI) [33]. The peptide was synthesized with the chelating agent 
diethylenetriaminepentaacetic acid (DTPA) at the amino terminus, followed by chelation to gadolinium (Gd) and 
covalent binding of the diamine to COOH groups using a carbodiimide crosslinker. An Aβ40 derivative based on the first 
30 amino acid residues with amine-modified carboxyl groups of glutamic and aspartic acid and containing Gd-DTPA-
aminohexanoic acid covalently linked to the N-terminal was subsequently proposed to overcome some problems 
associated with Gd-DTPA diamine modified Aβ40 (inherent problems of peptide cross-linking and decreased solubility 
during carbodiimide-mediated modification) [34]. Although several cationic proteins are known to cross the BBB by 
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AMT, the transport mechanism of diamine/polyamine-modified peptides/proteins has not yet been identified and may 
involve other processes such as carrier-mediated transport rather than simply electrostatic interactions [17]. 
 
 
Figure 2. Design strategies for transporting Aβ imaging agents through the blood brain barrier: A) Radiolabeled Aβ is bound to a 
linker domain, a 14-atom linker attached to biotin, which is bound by an avidin analogue such as streptavidin via a thiol-ether linkage 
(S) to the transport domain, which is comprised of either the OX26 murine monoclonal antibody (mAb) to the rat transferrin receptor  
(TfR), the 83-14 mAb to the human insulin receptor (HIR) or the R17-217 or 8D3 mAb to the mousse TfR; B) Radiolabeled Aβ is 
biotinylated at the amino terminus and is bound to a fusion protein, which is formed by fusion of avidin to the carboxyl terminus of 
the heavy chain of monoclonal antibodies, which is comprised of either the chimeric mAb against the mouse TfR or chimeric 
HIRmAb; C) Aβ is synthesized with the chelating agent diethylenetriaminepentaacetic acid (DTPA) at the amino terminus, followed 
by chelation to gadolinium (Gd) and covalent binding of the natural diamine (putrescine) to its carboxylic groups using a 
carbodiimide crosslinker. 
 
Aβ peptides are also proposed as therapeutic molecules in active immunization. Transgenic AD mice immunized with 
Aβ42 by systemic injection developed anti-Aβ amyloid antibodies, which decreased the amyloid plaque number and 
improved cognition [35-38]. The passive immunization led to similar conclusions [39-41]. The mechanism by which the 
antibodies act seems to involve their transport through the BBB and direct interaction with amyloid plaques. This is 
supported by the fact that the binding of anti-Aβ antibodies to Aβ deposits results in their disaggregation [42, 43]. The 
problem is that this seems to be achieved at the expenses of the BBB integrity and is associated to life-threatening side 
effects. The BBB transport of anti-Aβ antibodies was attributed to the adjuvants associated to the vaccine, specifically 
the complete Freund’s adjuvant, which contains heat-inactivated Mycobacterium. The solubilization of the 
mycobacterial cell results in a high content of mannan polysaccharide, which leads to the formation of anti-mannan 
antibody, which, in turn, induces a reversible BBB disruption [44, 45]. Active immunization of AD patients in clinical 
trials was suspended due to problems related to the cerebrovasculature such as stroke and encephalitis [46, 47]. Passive 
immunization also causes side effects, mainly BBB disruption and cerebral microhemorrhage, which were attributed to 
the increase of Aβ plasma concentration [48-51]. The mechanism of antibody transport to the brain during passive 
immunization is not entirely understood [42, 52]. It has been suggested that anti-Aβ antibodies cross the BBB slowly by 
extracellular pathways (residual leakiness of the BBB) [9, 52]. Peripheral Aβ peptide may also be responsible for 
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transporting the antibody across the BBB since the complex anti-Aβ antibody/Aβ was found to be more permeable to the 
barrier than the antibody alone [53]. In this case, the transport of the antibodies would be dependent on the Aβ plasma 
concentration, which is highly variable from patient to patient. There is also the hypothesis that anti-Aβ antibodies act by 
sequestering Aβ peptide in the circulation, altering the Aβ equilibrium between the brain and plasma (sink hypothesis) 
[40]. Such diverse hypotheses result from the different methodologies and antibodies used in the studies. Nevertheless, 
the disaggregation of the amyloid plaques in the brain is only possible if the anti-Aβ antibody is able to cross the BBB, 
which may or may not occur during immunization [39, 54]. A fusion antibody against amyloid deposits was developed 
aiming the combination of the following functionalities: crossing the BBB bidirectionally; binding to Aβ amyloid 
deposits and disaggregating them [55]. The antibody is composed of a single chain variable fragment (ScFv) antibody 
directed against the amino-terminal region of the Aβ peptide and a genetically engineered chimeric HIRmAb (Figure 3). 
The anti-Aβ ScFv antibody was fused to the carboxyl terminus of the CH3 region of the HIRmAb heavy chain by a two 
amino acid linker (Ser-Ser linker) [55]. In the central region, the fusion antibody contains the CH2-CH3 interface of the 
human IgG constant region, which is the binding site for the neonatal Fc receptor (FcRn) [55]. It was established that the 
fusion antibody was able to cross the BBB in Old World primates (rhesus monkey) and to bind and disaggregate Aβ 
fibrils in vitro (double-antibody ELISA experiments) and in vivo (intracerebral injection into the frontal cortex and 
hippocampus in transgenic mice since the HIRmAb is not recognized by the rodent insulin receptor) [55]. The fusion 
antibody was designed in such a way that, in addition to its influx from the blood to the brain, it will also efflux from the 
brain. This was achieved by the CH2-CH3 interface to enable the binding and transport via the BBB FcRn receptor. It 
was proposed that the transport of IgG molecules from the brain to the blood is mediated by a BBB FcRn receptor [56]. 
There is also some evidence that the same receptor could be involved in the clearance of anti-Aβ antibody/Aβ complexes 
[42]. However, a recent work showed that IgG transport from brain to plasma still occurs in FcRn knockout mice [57]. 
Although, the experimental results of the efflux of the fusion anti-Aβ antibody from the brain seem to point out for FcRn 
receptor-mediated transport, these data still need validation [55, 57].  
The polyamine modification has also been applied to anti-Aβ antibodies to increase their permeability at the BBB [15, 
58]. A rat mAb (AMY33) directed against a synthetic peptide corresponding to the first 28 amino acids of Aβ was 
cationized with hexamethylenediamine [15] and a domain specific antibody fragment F(ab)´2 of a mAb against fibrillar 
human Aβ42 was covalently linked to putrescine [58].  
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Figure 3. Fusion antibody for immune therapy of Alzheimer’s disease comprising three domains: the monoclonal antibody to the 
human insulin receptor (HIRMAb), the CH2–CH3 interface of the Fc neonatal receptor (FcRn) region and the anti-amyloid-β peptide 
single chain variable fragment (ScFv) fused to the CH3 region. Reprinted with permission from Boado et al. Bioconjugate Chem, 
2007, 18: 447-455. Copyright (2007) American Chemical Society. 
 
Due to the limited translational applications posed by the covalent binding of proteins to carriers that are able to cross 
the BBB, a method based on a peptide transporter that does not require covalent linkage has recently been proposed 
[59]. The peptide consists of 16 lysine residues and 20 residues (151-170) of the low-density lipoprotein receptor 
(LDLR)-binding domain of apolipoprotein E (ApoE). The lysine residues meet the criteria of binding strongly and non-
covalently to proteins. The domain of the ApoE mediates the BBB transport of the protein through LDLR-mediated 
transcytosis. The transport mechanism was not confirmed but the study demonstrated that the peptide carrier is able to 
deliver an antibody against Aβ to the brain of mice with AD after IV injection [59]. 
 
LIPID- AND POLYMER-BASED NANOPARTICLES 
Liposomes and polymeric nanoparticles are widely used in the preparation of drug delivery system formulations for 
parenteral administration. Some of the liposome or lipid-based formulations are already in clinical use [60, 61]. They 
normally do not cross the BBB and are rapidly removed from the bloodstream by cells lining the reticulo-endothelial 
system (RES) but their pharmacological properties can be relatively easily modified [62-64]. For example, coating the 
systems with polyethylene glycol (PEG) increases their half-life in the circulation due to steric stabilization and BBB 
permeability modification can be achieved by modifying the system surface with antibodies that undergo RMT [14, 62-
64]. In the study of nanoparticles for AD therapy different surface modifications have been tested: conjugation of 
monoclonal antibodies directed to the transferrin receptor of the BBB (OX-26) and against Aβ42 peptide to pegylated 
liposomes; coating polymeric particles with polysorbate 80, trimethylated chitosan or putrescine-modified F(ab’)2 
fragment of Aβ antibody (IgG4.1) (Figure 4 and Table 2). Liposomes and nanoparticles are versatile systems that can be 
used to encapsulate either lipophilic, amphiphilic or water-soluble molecules. The loading of the system needs always to 
be optimized according to the physico-chemical properties of the drug. 
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Figure 4. Surface modification of lipid- and polymer-based nanoparticles for crossing the blood-brain barrier (BBB) to treat 
Alzheimer’s disease. Polymer nanoparticles were coated with polysorbate 80, trimethylated chitosan or putrescine-modified F(ab’)2 
fragment of Aβ antibody (IgG4.1). Liposomes were prepared with peptide immunogen – two terminal palmitoylated lysine residues 
were covalently linked at each end of Aβ15 – and pegylated liposomes were conjugated to monoclonal antibodies directed to the 
transferrin receptor of the BBB (OX-26) and against Aβ42 peptide (see Table 2 for details). 
 
Liposomes 
The liposome based-system better studied for BBB delivery is an immunoliposome made of 
distearoylphosphatidylcholine (DSPC), cholesterol and a PEG-derivatized phosphatidylethanolamine (PE) to which the 
OX26 murine mAb was coupled [14, 63, 65, 66]. Both in vitro and in vivo studies demonstrated that OX26-targeted 
liposomes cross the BBB. Because of these promising findings, the system is also being studied for application in AD 
therapy [67]. Liposomes of DSPC, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[carboxy(polyethylene glycol)-2000] (DSPE-PEG2000) and biotinylated DSPE-PEG2000 (20:10:0.8:0.015–0.065 mole 
ratios) were prepared and linked to streptavidin followed by coupling to two different biotinylated antibodies at their 
surfaces: one directed to the transferrin receptor of the BBB (OX-26) and other against Aβ42 peptide [67]. Both 
antibodies were conjugated using the streptavidin-biotin technology but no details were provided on how the binding of 
the two different mAb was controlled. The liposomes were taken up by immortalized human brain capillary endothelial 
cells hCMEC/D3 but their BBB permeability needs to be further validated by in vivo tests [67, 68]. 
Liposomes functionalized with Aβ short sequences were proposed as vaccines and were tested in mice model of AD 
[69]. Each terminal end of the sequence 1-15 of Aβ (Aβ15) was coupled to one lysine-palmitic acid conjugate (with the 
appropriate length for stable insertion into the liposomal bilayer) (Figure 4) and the amino acid residues 1–16 of Aβ was 
conjugated with one lysine-PEG-DSPE at each peptide terminal side (PEGAβ16). They were then reconstituted in 
liposomes consisting of dimyristoyl phosphatidyl choline (DMPC), dimyristoyl phosphatidyl glycerol (DMPG), and 
cholesterol (9:1:7 molar ratios) [69]. The vaccines differed only on the distance between the antigen and the lipid anchor 
in the liposome; whereas Aβ15 is close to the surface, the Aβ16 has a spacer (PEG with 77 units) that separates it from the 
liposome surface. This led to different immune response and memory restoration on APPxPS-1 double-transgenic mice. 
The system with Aβ15 induced an immune response that restored the memory of the mice, whereas the spacer prevented 
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this effect [69]. The explanation appears to be associated to the different conformation of the Aβ sequences and 
generated immunoglobulins, which were predominately of the IgG class for Aβ15 liposome and of IgM for PEGAβ16 
liposome. The efficacy of the Aβ15 liposomes was assumed to be in part due to the fact that IgG antibodies could cross 
the BBB whereas IgM not.  
Polymeric nanoparticles 
Polymers that have been used to prepare nanoparticles for crossing the BBB include polybutylcyanoacrylate (PBCA), 
chitosan, poly(D,L-lactide-co-glycolide) (PLGA), poly(D,L-lactide) (PLA). PBCA nanoparticles coated with the nonionic 
surfactant polysorbate 80 (also known as Tween 80 or polyoxyethylene-20 sorbitan monooleate) were the first system 
proposed for drug delivery to the brain and have been intensely studied since then [70]. The commercially available AD 
drugs rivastigmine and tacrine were encapsulate in PBCA nanoparticles (Table 2) [71-73]. These drugs cross freely the 
BBB but a delivery system may improve their bioavailability in the brain and reduce their toxic side effects by releasing 
them in a sustained controlled manner. PBCA nanoparticles are normally prepared by anionic emulsion polymerization 
method by adding the monomer n-butyl cyanoacrylate to acidic medium containing a colloidal stabilizer (dextran) and 
coated with polysorbate 80. This system increased the concentrations of the cholinesterase inhibitors in the brain of 
healthy adult Wistar rats after IV injection by approximately 4-fold when compared to the free drug [71, 72]. The 
nanoparticle/rivastigmine formulation was studied in scopolamine-induced amnesia in mice model and showed to 
generate a faster regain of memory loss when compared to rivastigmine solution [73].  
Polysorbate 80-coated PBCA nanoparticles were also used to encapsulate radiolabeled 5-chloro-7-iodo-8-
hydroxyquinoline (clioquinol), a copper/zinc chelator, and curcumin, a polyphenolic compound [10, 74, 75]. Clioquinol 
is known to bind with high affinity to amyloid plaques and to inhibit the Aβ accumulation in AD transgenic mice and 
thus it is proposed as a promising in vivo amyloid-imaging agent. The molecule is able to cross the BBB but shows 
neurological side effects. The polysorbate 80-coated PBCA nanoparticles enhanced the brain uptake of the radiolabeled 
quinoline in both wild type and AD transgenic mice [76]. The application of curcumin, which is reported to possess anti-
amyloid and anti-tau hyperphosphorylation properties, is restricted by its insolubility in water. The encapsulated 
curcumin showed a mean residence time of 17 h and a concentration increase in the brain in healthy mice after IV 
injection when compared to the free drug (injection of nanoparticles at 5 mg/kg resulted in a maximum curcumin 
concentration of 34.1 ng/g in the brain after 0.083 hours, whereas the dose of 10 mg/kg curcumin solution led to levels 
of 25.7 ng/g after 0.5 hours) [75].  
Polysorbate 80-coated PBCA nanoparticles were in addition proven to be effective in transporting contrast agents for in 
vivo optical imaging in AD transgenic mice after IV injection: Texas red, a molecular imaging dye that binds senile 
plaques ex vivo, and Trypan blue, a plaque-binding red fluorescing diazo dye that does not cross the BBB [77]. 
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Adsorbed Alexa-488–conjugated anti-Aβ antibody (6E10) to the nanoparticle surface stained amyloid plaque 15 min 
after peripheral injection and peaking at 2 hours. A gadolinium (Gd)-based MRI contrast agent also adsorbed onto 
PBCA NPs was detected in the brain of wild-type mice: 5.34% of the injected nanoparticle-loaded gadolinium per gram 
of tissue in the brain compared with only 0.009% injected dose of free gadolinium per gram of tissue 2.5 hours after 
administration [77]. This work took advantage of the advanced imaging techniques such as four-dimensional real-time 
two-photon and MRI to confirm the brain uptake of polysorbate 80-coated PBCA nanoparticles, which occurs with a 
time constant of approximately 18 min. Polystyrene core/PBCA shell nanoparticles coated with polysorbate-80 and 
containing thioflavins, which bind to amyloid fibrils, were detected in APP/PS1 transgenic mice upon 
intracerebroventricular injection of the nanoparticle formulation but not after IV infusion [78].  
The mechanism of BBB transport of polysorbate 80-coated PBCA nanoparticles is still debatable. It has previously been 
proposed that they are transported via RMT triggered by the adsorption of serum protein apolipoprotein E (ApoE) in the 
plasma but some evidences seem to contradict this mechanism [62, 79]. They are the following: i) ApoE adsorption is 
not specific to polysorbate 80 coated surfaces; ii) poly-(methylmethacrylate) or polystyrene nanoparticles coated with 
this surfactant are not delivered to the brain; iii) no brain uptake occurs with drug-polysorbate 80 control solutions. 
Because of such facts, a nonspecific BBB permeabilization mechanism related to the opening of the tight junctions 
between the brain endothelial cells and a synergistic toxicity effect of polysorbate 80 and PBCA nanoparticles was 
suggested [80]. Polysorbate 80 is known to cause BBB permeabilization and PBCA nanoparticles (coated or uncoated) 
were found to be toxic to mice and to induce permeabilization of an in vitro BBB model. However, the generalized toxic 
effect on the BBB by polysorbate 80-coated PBCA nanoparticles was not yet confirmed and instead specific 
mechanisms involving recruitment of the cerebral capillaries, stimulation of endocytosis and modulation of the tight 
junctions permeability have been proposed [81]. 
Chitosan is a polysaccharide consisting of N-acetyl-D-glucosamine and D-glucosamine monomers obtained by alkaline 
N-deacetylation of chitin, a polymer commercially extracted from shrimp shells. Because of its abundant availability, 
non-toxicity, low-immunogenicity and mucoadhesivity, chitosan is extensively studied in drug delivery. Nanoparticles 
of chitosan can be prepared by different methods including ionotropic gelation using a cross linker and have been 
proposed for the delivery of Aβ peptide fragments and tacrine [82, 83]. The brain uptake efficiency of Aβ 
fragments/chitosan nanoparticles was 80.6% but their BBB permeation might be associated to changes in BBB integrity 
since Freund’s adjuvant was also administered [82].  
Chitosan nanoparticles were coated with putrescine-modified F(ab’)2 fragment of Aβ antibody (IgG4.1) by electrostatic 
interactions to target cerebrovascular amyloid deposits and brain parenchymal plaques [84]. The accumulation of 125I 
labeled nanoparticles in the brain of Wild type mice following IV administration was 8 to 11 times higher than the 
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control system (chitosan nanoparticles coated with bovine serum albumin), although their plasma clearance was 9 times 
higher [84]. The pharmacokinetic data excluded the release of the antibody fragment from the particle surface in the 
plasma. In addition, in vitro studies demonstrated the transcytosis of the antibody-coated nanoparticles through a BBB 
endothelial cell model, which is attributed to the polyamine modification of the anti-amyloid antibody fragment [58]. 
The in vivo studies carried out for tacrine-loaded chitosan nanoparticles provided data concerning the drug distribution 
only in peripheral organs; neither the brain uptake nor the pharmacodynamic effects were evaluated [83]. 
PLA and PLGA are FDA-approved, biocompatible and resorbable via natural pathways. Because of that, they are 
considered the most promising biodegradable polymers for the preparation of nanoparticles including those for drug 
transport to the central nervous system. Nanoparticles made of PLA or PLGA are mainly prepared using the 
emulsion/solvent evaporation technique or the precipitation solvent diffusion technique and stabilized with PEG coating 
to reduce uptake by the RES. The cholinesterase inhibitors donepezil and rivastigmine were incorporated in PLGA 
particles and their pharmacodynamic effects were evaluated using mice or rat models [73, 85]. Although in vivo studies 
showed improvement in learning and memory after nanoparticle parenteral administration, the BBB permeation of the 
systems should be considered with precaution. PLGA nanoparticles, in the absence of surface modifications, are not 
expected to cross the BBB [62]. Since, in that works, the nanoparticles were not modified, a possible explanation for the 
observed effects is that PLGA nanoparticles reach the brain by adjuvant-mediated transport; the study with donepezil 
reports the co-administration of mannitol (5%), a hyperosmolar agent that disrupts the BBB, and polysorbate 80 (0.1%) 
[85]. Another possibility is that the nanoparticles allow the sustained release of the drug in the plasma and the free drug 
reaches the brain.  
PLGA nanoparticles coated with trimethylated chitosan were shown to cross the BBB [86]. PLGA nanoparticles were 
prepared with coenzyme Q10(Co-Q10) as a model drug or with 6-coumarin as a fluorescence probe and trimethylated 
chitosan was conjugated to the particle surface by carbodiimide-mediated modification [86]. Fluorescence microscopy 
measurements showed that after IV injection in CD-1 mice the trimethylated chitosan-coated nanoparticles containing 6-
coumarin were accumulated in the cortex, paracoele, the third ventricle and choroid plexus epithelium, whereas 
uncoated particles were not detected.  Experiments in AD transgenic mice attested that the system with Co-Q10 improves 
spatial memory and reduces the number of senile plaques. The positively charged coating is expected to facilitate the 
active transport of the particles via AMT [16, 87]. However, positively charged particles can be opsonized with plasma 
proteins leading to their rapid clearance and to the activation of the complement system initiating an inflammatory 
response. This might be prevented in part by adding PEG molecules to the nanoparticle surface.  
Other polymeric system proposed for AD therapy that was tested in vivo is based on N-isopropylacrylamide, 
vinylpyrrolidone and acrylic acid. The nanoparticles were synthesized by free radical mechanism and loaded with 
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curcumin (NanoCurcTM) [88]. After 16 h from the last intraperitoneal injection of the nanoparticles at a dose of 25 
mg/kg twice daily and for 4 weeks in athymic mice the average curcumin concentration in the brain was 0.32 µg/g. The 
brain level of curcumin injected alone was not determined but it is described to be approximately 3 to 30 times less than 
the brain level of curcumin after NanoCurcTM administration. The results also showed that caspase 3 and caspase 7 
activities were significantly decreased in the cortical lysate of NanoCurcTM-treated mice, which may ameliorate 
pathological neuronal cell death observed in AD. 
Table 2. Nanopharmaceuticals consisting of AD drugs and nanoparticles that were validated in rodent models by demonstrating their 
effective therapeutic potential and/or brain uptake in AD transgenic/healthy rodent models.  
Nanoparticles Cargos Main observations Ref. 
 DMPC:DMPG: 
cholesterol liposomes 
(9:1:7 molar ratios) 
Aβ short sequences Induction of an immune response  
Improvement of memory in AD transgenic mice 
No studies on the BBB permeation 
  
[69] 
Polysorbate 80-coated 
PBCA nanoparticles 
Tacrine 
Rivastigmine 
4-fold increase of the concentration in the brain of 
healthy adult Wistar rats compared to the free drug 
Improvement of the pharmacodynamics effects  
[71-
73] 
 
Radiolabeled-clioquinol Enhancement of the brain uptake in both wild type 
and AD transgenic mice after IV injection 
[76] 
 
Curcumin Increase of the polyphenol concentration in the 
brain when compared to the free drug  
[75] 
 
Texas red 
 Trypan blue  
Alexa-488–conjugated anti-Aβ antibody  
Gd-based contrast agent 
Brain uptake with a time constant of 18 min 
Staining of amyloid plaques, cerebral amyloid 
angiopathy, and neuronal/glial cell bodies in living 
AD transgenic mice; 5.34% of nanoparticle-loaded 
Gd per gram of tissue in the brain 
[77] 
Chitosan 
nanoparticles 
Aβ fragments  Administered together with Freund’s adjuvant 
A brain uptake efficiency of 80% in Kunming mice  
[82] 
 
F(ab’)2 fragment of Aβ antibody modified 
with putrescine (as coating) 
Brain accumulation in Wild type mice following IV 
administration 
[84] 
Trimethylated 
chitosan coated 
PLGA nanoparticles 
6-coumarin  
Coenzyme Q10 
Accumulation in the cortex, paracoele, the third 
ventricle and choroid plexus epithelium in CD-1 
mice after IV injection  (with coumarin) 
Improvement of the spatial memory and reduction 
of senile plaques (with Co-Q10) 
[86] 
Nanoparticles of N-
isopropylacrylamide, 
vinylpyrrolidone and 
acrylic acid  
Curcumin ~0.322 ng curcumin/mg of brain tissue after 16 h of 
intraperitoneally injected  
[88] 
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CHEMICAL MODIFICATION OF AD THERAPEUTIC PEPTIDES  
The mechanism of action of peptides proposed for AD has been recently reviewed [89, 90]. The studies on AD 
therapeutic peptides focus mainly on the inhibition of Aβ peptide aggregation and neurotoxicity [90-92]. There is only 
one peptide described so far that targets tau protein [93]. Therapeutic peptides may be transported through the BBB by 
non-saturable pathways in sufficiently doses to affect the central nervous system but they are prone to rapid degradation 
by proteolytic enzymes, which will dramatically decrease their concentration in the blood. There are few works related 
to therapeutic peptides that were designed or modified to have prolonged plasma half-life time and proven to cross the 
BBB (Table 3). These peptides were shown to reduce the amyloid deposition in rodent AD models or to have potential 
therapeutic effect in AD patients enrolling clinical trials [89].  
The 11 amino acid beta-sheet breaker peptide (iAβ11), developed based on the internal hydrophobic domain of Aβ 
peptide (residues 17-21, LVFFA) and on proline [94], was modified by polyamine covalent binding to improve its BBB 
permeability. In addition the L-amino acids were substituted to D-enantiomeric residues to increase its resistance to 
proteolysis in the plasma [95]. The iAβ11 was the starting point for the design of a pentapeptide, LPFFD, with increased 
efficacy and better BBB permeability owing to its reduced molecular weight but it turned out to be rapidly degraded 
after few minutes in the circulation. Several chemical modifications were performed to improve its proteolysis 
resistance, stability, solubility and BBB permeability and they include: N-terminal acetylation, C-terminal amidation, N-
methylation and conjugation to PEG [96-99]. The sequence acetylated at the N-terminus and amidated at the C-terminus 
has been demonstrated to reach the brain of transgenic mice after injected intravenously [96, 98]. The additional N-
methylation between proline and phenylalanine did not change the brain uptake rate of the peptide but improved 
significantly the enzymatic stability in rat brain homogenate [97]. The sequence LPFFD binds to Aβ peptide inhibiting 
its aggregation by blocking the formation of β-sheet conformation species and even the conjugation of long PEG chains 
(molecular weight 2000 or 5000 Da) did not block this binding affinity [99]. This β-sheet breaker peptide is known to 
disrupt amyloid fibrils, inhibit Aβ in vitro cell neurotoxicity and reduce cerebral amyloid deposition in vivo. The 
substitution of one phenylalanine with tyrosine and the amidation of the C-terminal carboxylate resulted in a sequence 
with high affinity for Aβ amyloid fibrils that was able of preventing neurotoxicity triggered by Aβ42, decreasing tau 
aggregation, crossing the BBB and protecting the synapses against the excitatory action of fibrillar Aβ42 [100-102]. 
Other β-sheet breaker peptide, based as well on the hydrophobic central Aβ peptide domain (residues 17-21), the 
sequence N-methyl-LVFFL with D-enantiomeric residues has reached clinical trials [103, 104]. The modifications 
allowed for increased biostability and prolonged elevated plasma levels. Aβ residues 12–28 where valine in position 18 
was replaced by proline to avoid intrinsic toxicity associated with its residual capacity to form fibrils was proposed for 
the inhibition of the interaction between Aβ peptide and apolipoprotein E4 (ApoE4), which is considered a pathological 
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chaperone of Aβ conformational changes [105]. The sequence, synthesized with D-amino acids and end-protected 
(amidation of the C-terminus and acetylation of the N-terminus), reached the brain parenchyma of transgenic AD mice. 
The findings demonstrated that this sequence was able to block the interaction between Aβ and ApoE (competitive 
inhibition assay) and inhibit Aβ deposition in vivo, although the mechanism of action and the benefits of the approach of 
blocking Aβ-ApoE interaction for AD treatment are not clear [89, 105].  
A small dipeptide that was designed by the principles of peptide chemistry for oligomer-inhibition (iterative selection 
cycles) was found to possess high serum stability and to cross the BBB [106]. The dipeptide consists of D-tryptophan, 
which is the aromatic recognition motif responsible for interacting with the aromatic core of Aβ, and α-aminoisobutyric 
acid (Aib), which is considered a strong β-sheet breaker (Cα-methylation β-breakage strategy). This dipeptide prevents 
the oligomerization of Aβ peptide, inhibits its toxicity Aβ towards cultured cells and reduces amyloid deposits in the 
brain of AD transgenic mice improving their cognitive performance [106].  
Different mirror-image phage display screening using D-enantiomeric Aβ42 as a target under conditions where 
monomers or small oligomers of Aβ42 are the dominating species resulted in the selection of a D-peptide (D3) that has 
been shown to reduce amyloid plaque load and to improve the cognitive performance of AD transgenic mice after being 
orally administered [107]. D3 was shown to cross the BBB significantly in an in vitro BBB cell culture model 
suggesting that the peptide may be delivered to the brain but in vivo studies need to be carried out to confirm this 
hypothesis [108]. 
An apolipoprotein A-I (apo A-I) mimetic peptide (D-4F) that inhibits, in the presence of pravastatin, atherosclerotic 
lesion formation and decreases brain arteriole inflammation, was tested in transgenic AD mice and shown to reduce 
amyloid deposition [109]. Although an inflammatory component may contribute to the AD pathogenesis, the role of 
inflammation in the disease is not clear. D-4F was shown to be effective in AD mice after oral administration, lowering 
insoluble Aβ levels and improving their cognitive function. In addition, there was a decrease in the number of activated 
microglia and astrocytes, which are responsible for producing cytokines, oxidized lipids, and other pro-inflammatory 
molecules [109]. The mechanism of action of D-4F in AD mice is still not known. The peptide was shown to modulate 
the inflammatory properties of circulating lipoproteins, particularly HDL. But it was not determined if the peptide enters 
the brain as well as it is not clear if the peptide alone would inhibit Aβ deposition (D-4F was tested with pravastatin). 
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Table 3. Peptides that were shown to have a therapeutic effect and/or to reach the brain in AD transgenic animal models. 
Sequence Strategy to improve the stability in blood Main observations Ref. 
RDLPFFPVPID 
(iAβ1 or iAβ11) 
 
All D-amino acids + 
covalent binding of 
putrescine (to increase BBB 
permeability)  
 
Inhibition of Aβ fibrillogenesis  
Only 6% degradation in rat plasma at 15 min after IV 
injection   
5-7 fold increase in BBB permeability compared to non-
modified sequence  
(note: for in vivo studies, Phe at position 5 was 
substituted with Tyr to allow radioiodination) 
[95] 
LPFFD 
(iAβ5) 
N-terminal acetylation + C-
terminal amidation (Ac-
LPFFD-NH2) +  
N-methylation of amide 
between Pro and Phe (Ac-
LP-(NMe)-FFD-NH2) 
Reduction in amyloid deposition and reversion of 
memory impairment in transgenic AD models ∼0.1% of the IV injected dose in mice reaches the brain  
[96-98] 
 
 
 
Replacing one Phe with Tyr 
+ C-terminal amidation 
(LPYFD-amide) 
 
 
Strong binding affinity to Aβ fibrils 
Protection against the synaptotoxic effect of aggregated 
Aβ in rat  ∼0.3% of the intraperitoneally injected dose reaches the 
brain 
[100-102] 
 
N-methyl-LVFFL-NH2  
(PPI-1019) 
N-terminal methylation + 
C-terminal amidation + all 
D-amino acids  
Prolonged elevated plasma levels  
Completed Phase I and Phase II clinical trial 
[103, 104] 
NH2-D-Trp-Aib-OH D-amino acid + α-
aminoisobutyric acid (Aib, 
selected for its β-sheet 
breaker activity, but is non-
metabolized and crosses the 
BBB) 
Reduction in amyloid deposition and improvement of 
cognitive performance of AD model mice  
Orally bioavailable (39%) 
4–8%, depending on the route of administration, crosses 
the BBB  
[106] 
Ac-
VHHQKLPFFAEDVGSNK-
NH2 
(iAβ12-28P) 
N-terminal acetylation + C-
terminal amidation + All D-
amino acids 
 
Inhibition of Aβ/apoE interaction  
Reduction in Aβ deposition in transgenic AD mice 
Plasma half-life is 62 minutes  
BBB permeable  
[105] 
RPRTRLHTHRNR All D- amino acids Inhibition of Aβ toxicity in vitro 
Reduction of amyloid plaque load and improvement of 
the cognitive performance of AD transgenic mice 
BBB permeability assessed only by in vitro studies 
[107, 108] 
Ac-
DWFKAFYDKVAEKFKEAF
-NH2 
N-terminal acetylation + C-
terminal amidation + All D-
amino acids 
Reduction in amyloid deposition  
Improvement of the cognitive function in AD transgenic 
mice 
Remains intact in the circulation after oral administration 
No studies on the BBB permeation 
[109] 
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FUTURE PERSPECTIVE 
The application of nanomedicines to the treatment and prevention of AD remains experimental. This review summarizes 
the systems that were shown to cross the BBB or that were validated in in vivo studies by demonstrating their effective 
therapeutic potential (Figure 2, Table 1 and 2). However many other nanopharmaceuticals have already been proposed 
for the treatment of AD. The considerable progress in research in drug delivery systems will resolve safety and toxicity 
issues and will contribute to the understanding of the mechanism of transport through the BBB. Effective methods of 
drug delivery to the central nervous system are expected within the next 10 years [110]. Future studies will contribute to 
the optimization of drug delivery systems that have already been shown to be effective in in vivo models.  
The delivery strategies based on antibodies against the BBB endogenous receptors for AD diagnosis and therapy seem to 
preserve the BBB integrity. They are delineated to deliver the molecules by transcytosis either specific (RMT) or 
nonspecific (AMT). Further studies are needed to validate the transport mechanisms. In the case of immunotherapy, the 
antibodies should be engineering in such a manner that they are transported across the BBB and that they allow the 
complex anti-Aβ antibody/Aβ peptide to be rapidly cleared from the brain and from peripheral tissues [5].  
Many nanoparticles already proposed for drug delivery to the brain such as pegylated liposomes coated with glutathione 
or exosomes (small membranous vesicles, 50–130 nm in diameter, that derive from the invagination of endosomal 
compartments secreted by most cell types) still need validation for AD treatment and they will certainly be considered. 
Significant results have already been achieved in respect to the functionalization or coating of nanoparticles. For 
example, the accessibility and flexibility of the specific ligand improve if it is attached at the terminus of PEG chains 
rather than directly bound to the surface of the liposome or nanoparticle. This is mainly due to the shielding effect of 
PEG chains, which prevent the interaction between the bound ligand and its receptor. Such effect can be reduced using 
PEG with low molecular weight (2000 or lower) but the more suitable strategy seems to be to link the vector directly to 
the PEG chains. 
Concerning the delivery of AD therapeutic peptides, the strategies are common to that used to improve the half-life time 
of the class of peptide/protein drugs and basically are terminal modification (N-acetylation; C-amidation), substitution of 
L-amino acids with D-amino acids, conjugation to PEG and co-administration of specific enzyme inhibitors. However, 
these modifications should be carried out based on the knowledge of the enzymatic susceptibility of the molecule. For 
AD treatment, the peptides have to reach the brain parenchyma, thus additional modification may be necessary. 
Following the general tendency of AD drug development, the number of AD therapeutic peptides has significantly 
increased during the last years but studies on their delivery to the brain are deficient and need to be included in the early 
peptide discovery stage.  
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The effort to discover new drugs for AD should necessarily be combined with a BBB drug-targeting program to 
producing a cure, or at least a nanopharmaceutical that slows the progression of the disease. Above all, it is essential to 
focus on the optimization and validation of the systems that have shown promising results in preclinical studies. 
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